It is a potential competitor to Novartis’ blockbuster Cosentyx (secukinumab) and clinical evidence for its use in dermatology and rheumatology is already stacking up. There was little indication ...

The BE RADIANT trial pitted bimekizumab against Novartis’ Cosentyx (secukinumab) in the treatment of adults with moderate-to-severe psoriasis, and according to UCB is the first study to compare ...